×

Message

EU e-Privacy Directive

This website uses cookies to manage authentication, navigation, and other functions. By using our website, you agree that we can place these types of cookies on your device.

View e-Privacy Directive Documents

You have declined cookies. This decision can be reversed.

Cardiac Therapy: cardiac hypertrophy therapy with biologics

RhoGEF12 inhibition for the prevention and therapy of cardiac hypertrophy, -fibrosis, and -failure

0603-4414-MSG-WA

Background

Heart failure is a disabling and potentially deadly condition which affects 1-2% of adults in developed countries; in the population above 65 years the incidence increases to 6–10% (McMurray and Pfeffer 2005). Possible causes include increased pressure or volume load, as found in arterial hypertension or valve disease. To compensate reduced cardiac output, structural cardiac remodeling is initiated, including cardiac hypertrophy and fibrosis. This initially compensatory reaction may counterproductively reinforce the clinical signs of heart failure.

So far, the mechanisms underlying the transition from hypertrophy to heart failure are not well defined and thus therapeutic options are limited.

Technology

Scientists from the Max Planck Institute for Heart and Lung Research have identified a key molecule responsible for the development of cardiac hypertrophy, namely the RhoGEF12 protein (or LARG). Inactivation of RhoGEF12-dependent RhoA activation protects the heart from hypertrophy development, cardiomyocyte apoptosis, fibrosis, and the development of chronic heart failure. Mice with inducible, cardiomyocyte-specific inactivation of the RhoGEF12 (cmc-GEF12-KO) were protected from cardiac hypertrophy and fibrosis in two models of pressure overload, and their cardiac output function was improved compared to wt mice. Importantly, also in mice with preexisting hypertrophy, induction of RhoGEF12 deficiency protects from cardiac decompensation, resulting in significantly increased longterm survival.


We are looking for a collaboration- and/or licensing partner who is interested in this approach and eager to develop these scientific achievements into a marketable good.

 

http://www.max-planck-innovation.de/en/industry/technology_offers/therapeutics/article.php?RhoGEF12%20inhibition%20for%20the%20prevention%20and%20therapy%20of%20cardiac%20hypertrophy%2C%20-fibrosis%2C%20and%20-failure&id=9970

Attachments:
Download this file (0603-4414-MSG-WA_EN.pdf)0603-4414-MSG-WA_EN.pdf[RhoGEF12 inhibition for the prevention and therapy of cardiac hypertrophy, -fibrosis, and -failure]416 kB
REGISTERED: Handelsregister Schwyz
COMPANY NUMBER: CH-1029-379-06
TAX NUMBER: 1029-379-06
Copyright © 2017. All Rights Reserved.
Institute for Biomodulation Medicine AG

SCHWERZISTRASSE 4, CH-8807 FREIENBACH (SZ)
PHONE: +41 41 5003753 FAX: +41 41 5003754
EMAIL: INFO@BIOMODULATION.ORG

logo

INSTITUTE FOR BIOMODULATION
MEDICINE

0.png1.png0.png0.png1.png6.png5.png1.png
Today135
Yesterday460
This week595
This month1767
Total1001651

Tuesday, 07 December 2021 06:18